{"id":"relugolix-estradiol-norethindrone-acetate","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Vaginal bleeding/spotting"},{"rate":null,"effect":"Mood changes"}]},"_chembl":null,"_dailymed":{"setId":"fc3feb73-cc84-43a8-aa32-b262460495e8","title":"MYFEMBREE (RELUGOLIX, ESTRADIOL HEMIHYDRATE, AND NORETHINDRONE ACETATE) TABLET, FILM COATED [SUMITOMO PHARMA AMERICA, INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Relugolix is a non-peptide GnRH antagonist that rapidly suppresses gonadotropins, reducing estrogen production and providing pain relief in endometriosis. The combination with estradiol and norethindrone acetate (a progestin) replaces hormones to alleviate vasomotor and other menopausal symptoms that would otherwise occur from the GnRH antagonism, while maintaining the therapeutic benefit of low estrogen for endometriosis management.","oneSentence":"Relugolix suppresses luteinizing hormone and follicle-stimulating hormone by antagonizing GnRH receptors, while estradiol and norethindrone acetate provide hormone replacement to manage menopausal symptoms in women with endometriosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:45:06.567Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain associated with endometriosis in women of reproductive potential"}]},"trialDetails":[{"nctId":"NCT07100782","phase":"PHASE3","title":"Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-12-08","conditions":"Endometriosis, Pelvic Pain","enrollment":130},{"nctId":"NCT04756037","phase":"PHASE3","title":"Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2021-03-18","conditions":"Contraception","enrollment":1020},{"nctId":"NCT05538689","phase":"PHASE4","title":"Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-11-20","conditions":"Metrorrhagia, Pelvic Pain, Menorrhagia","enrollment":""},{"nctId":"NCT06279195","phase":"PHASE2","title":"Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment","status":"WITHDRAWN","sponsor":"Endeavor Health","startDate":"2024-06-01","conditions":"Pelvic Pain","enrollment":""},{"nctId":"NCT06953076","phase":"","title":"Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-05-02","conditions":"Uterine Bleeding, Uterine Leiomyomas, Uterine Hemorrhage","enrollment":111},{"nctId":"NCT05862272","phase":"PHASE3","title":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","status":"RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2023-08-14","conditions":"Uterine Fibroids, Endometriosis","enrollment":1000},{"nctId":"NCT05739136","phase":"","title":"MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2025-04-30","conditions":"Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk","enrollment":530},{"nctId":"NCT06439524","phase":"PHASE3","title":"The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Main Line Health","startDate":"2024-08-15","conditions":"Endometriosis","enrollment":110},{"nctId":"NCT03751124","phase":"PHASE3","title":"Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-10-16","conditions":"Uterine Leiomyoma, Uterine Fibroids","enrollment":229},{"nctId":"NCT03412890","phase":"PHASE3","title":"LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-10-19","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":477},{"nctId":"NCT03654274","phase":"PHASE3","title":"SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-05-22","conditions":"Endometriosis","enrollment":802},{"nctId":"NCT03103087","phase":"PHASE3","title":"LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-06-14","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":382},{"nctId":"NCT03049735","phase":"PHASE3","title":"LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-26","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":388},{"nctId":"NCT04714554","phase":"PHASE1","title":"A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2021-01-06","conditions":"Healthy","enrollment":43},{"nctId":"NCT03204331","phase":"PHASE3","title":"SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-11-01","conditions":"Endometriosis Related Pain","enrollment":623},{"nctId":"NCT03204318","phase":"PHASE3","title":"SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-12-07","conditions":"Endometriosis Related Pain","enrollment":638}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MVT-601","MVT-601A","MYFEMBREE"],"phase":"marketed","status":"active","brandName":"Relugolix + Estradiol + Norethindrone Acetate","genericName":"Relugolix + Estradiol + Norethindrone Acetate","companyName":"Sumitomo Pharma Switzerland GmbH","companyId":"sumitomo-pharma-switzerland-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Relugolix suppresses luteinizing hormone and follicle-stimulating hormone by antagonizing GnRH receptors, while estradiol and norethindrone acetate provide hormone replacement to manage menopausal symptoms in women with endometriosis. Used for Moderate to severe pain associated with endometriosis in women of reproductive potential.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}